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Abstract
Meniere’s disease is an episodic vestibular syndrome associated with sensorineural hearing loss (SNHL) and tinnitus. Patients
with MD have an elevated prevalence of several autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus,
ankylosing spondylitis and psoriasis), which suggests a shared autoimmune background. Functional variants of several
genes involved in the NF-kB pathway, such as REL, TNFAIP3, NFKB1 and TNIP1, have been associated with two or more
immune-mediated diseases and allelic variations in the TLR10 gene may influence bilateral affectation and clinical course in
MD. We have genotyped 716 cases of MD and 1628 controls by using the ImmunoChip, a high-density genotyping array
containing 186 autoimmune loci, to explore the association of immune system related-loci with sporadic MD. Although no
single nucleotide polymorphism (SNP) reached a genome-wide significant association (p,1028), we selected allelic variants
in the NF-kB pathway for further analyses to evaluate the impact of these SNPs in the clinical outcome of MD in our cohort.
None of the selected SNPs increased susceptibility for MD in patients with uni or bilateral SNHL. However, two potential
regulatory variants in the NFKB1 gene (rs3774937 and rs4648011) were associated with a faster hearing loss progression in
patients with unilateral SNHL. So, individuals with unilateral MD carrying the C allele in rs3774937 or G allele in rs4648011
had a shorter mean time to reach hearing stage 3 (.40 dB HL) (log-rank test, corrected p values were p = 0.009 for
rs3774937 and p = 0.003 for rs4648011, respectively). No variants influenced hearing in bilateral MD. Our data support that
the allelic variants rs3774937 and rs4648011 can modify hearing outcome in patients with MD and unilateral SNHL.
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Introduction
Meniere’s disease (MD) is a chronic disorder affecting the inner
ear characterized by fluctuating sensorineural hearing loss
(SNHL), episodes of vertigo, tinnitus, and aural fullness and it
can affect both ears in 10–40% of cases [1]. The etiology and
pathogenesis remain unknown, although one-third of MD cases
may have an aberrant response of the adaptive or innate immune
system, the immunological mechanisms involved have not been
investigated [2].
Several mechanisms may explain the development of immune-
mediated inner ear disease (IED): a) cross-reactions with a cross-
reactive epitope (antibodies cause accidental inner ear damage
because the ear shares epitopes with a potentially harmful
substance, virus or bacteria) as suspected for some inflammatory
diseases [3], b) damage to the inner ear caused by pro-
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inflammatory cytokines such as IL-1B [4], [5] or TNF [6] as in
some autoimmune diseases, or c) inappropriate immune response
or intolerance to harmless unrecognized substances combined with
genetic factors that modify the immune response as in allergies [2].
IED and MD may have an overlapping phenotype and
autoimmune mechanisms could be associated with the pathophys-
iology of MD. Some evidence support this hypothesis including the
response to steroids therapy, the finding of elevated levels of
autoantibodies or circulating immune complexes (CIC) in the
serum of some patients with MD against inner ear antigens and
the association of allelic variants of MHC class I polypeptide-
related sequence A (MICA) and Toll-like receptor 10 (TLR10,
rs11096955) gene with hearing loss progression in patients with
MD [7], [8].
These findings together with the elevated prevalence of several
autoimmune diseases such as rheumatoid arthritis (RA), systemic
lupus erythematosus (SLE), ankylosing spondylitis (AS), and
psoriasis in patients with MD, suggest an autoimmune component
[9], [10].
Nuclear factor kB (NF-kB) is a crucial pleiotropic transcription
factor (TF) which regulates inflammation and the innate and
adaptive immune response [11]. Five members of this transcrip-
tion factor family have been identified: RELA (p65), RELB, REL
(c-Rel), NF-kB1 (p105) and NF-kB2 (p100). Of note, p105 and
p100 are pro-forms proteolytically processed to p50 and p52 [12].
All members of the NF-kB family harbor an N-terminal Rel
homology domain (RHD), which interacts with DNA elements
and mediates homo- and heterodimerization. The complex p65–
p50 is the most abundant form of heterodimer of the NF-kB family
and it keeps in an inactive state in the cytoplasm bound to proteins
of the IkB family, which are inhibitors of NF-kB [13].
In its canonical pathway, excitatory signaling can be mediated
through Toll-like receptors (TLRs), Interleukin-1 receptor (IL-1R),
tumor necrosis factor receptor (TNFR) and antigen receptors.
Several genes involved in the regulation of NF-kB pathway have
been associated with autoimmune disorders. So, ubiquitin-
conjugating enzyme E2L3 (UBE2L3), which ubiquitylates p105
for its degradation, tumor necrosis factor alpha-induced protein 3
(TNFAIP3, also known as A20), an ubiquitin-editing enzyme with
determines NF-kB activity or TNFAIP3-interacting protein
(TNIP1) which inhibits TNF-induced NF-kB -dependent gene
expression have genetic variants associated with several autoim-
mune diseases [14].
The genotyping of large cohorts of patients with several
autoimmune diseases in genome-wide association studies has
shown that most of these diseases share multiple susceptibility loci
(www.immunobase.org) [14]. Among them, several genes in the
NF-kB pathway are associated with two or more immune-
mediated diseases, such as inflammatory bowel disease (REL,
TNFAIP3 and NFKB1), psoriasis (REL, TNFAIP3, NFKB1 and
TNIP1), coeliac disease (REL and TNFAIP3), rheumatoid
arthritis (REL and TNFAIP3), type 1 diabetes (T1D) (TNFAIP3),
systemic lupus erythematous (SLE) (TNFAIP3 and TNIP1),
multiple sclerosis and primary biliary cirrhosis (NFKB1) (Table 1).
We have used the ImmunoChip, a high-density genotyping
array which includes 186 loci previously associated with 12
autoimmune diseases, to explore the association of these loci with
MD and to evaluate the role of functional variants of genes
involved in the NF-kB pathway with MD and their potential effect
on the hearing outcome of the disease [14].
Materials and Methods
Study samples
This study was approved by the ethics committees of all the
recruiting centers and all participating individuals gave written
informed consent. This study was approved by the ethics
committee for clinical research from Almerı´a (Comite´ E´tico de
Investigacio´n provincial de Almerı´a), Jae´n (Comite´ E´tico de
Investigacio´n provincial de Jae´n), Galicia (Comite´ Autono´mico de
E´tica de la Investigacio´n de Galicia), Asturias (Comite´ E´tico de
Investigacio´n Clı´nica Autono´mico de Asturias), Las Palmas (CEIC
del Hospital de Gran Canaria Dr. Negrin), Navarra (Comite´ E´tico
de Investigacio´n Clı´nica Autono´mico de Navarra), Extremadura
(Comite´ E´tico Autono´mico de Extremadura), Madrid-Getafe
(CEIC A´rea 10 - Hospital Universitario de Getafe), Arago´n
(Comite´ E´tico de Investigacio´n Clı´nica de Arago´n) and Salamanca
(Comite´ E´tico de Investigacio´n Clı´nica A´rea de Salud de
Salamanca). All the procedures described were performed in
accordance with the highest ethical standards on human
experimentation, the Helsinki Declaration of 1975.
We recruited a total of 716 patients who were diagnosed with
definite MD according to the diagnostic scale for MD of the
American Academy of Otolaryngology Head and Neck Surgery
(AAO-HNS) [15] and 1628 control volunteers in a case–control
study.
The diagnosis of MD was established according to the clinical
guidelines defined by the Committee on Hearing and Equilibrium
of the AAO-NHS in 1995 [15]. A complete neuro-otological
evaluation including otoscopy, a pure-tone audiometry, nystagmus
examination and caloric testing was carried out in all cases.
Moreover, the protocol of diagnosis included a brain MRI to
exclude other possible causes of neurological symptoms. Patients
were followed with serial audiograms at each visit to monitor
hearing loss from the initial diagnosis. The following clinical
variables were studied in our series: gender, age, hearing stage,
duration of the disease, bilateral SNHL, age of onset, type of
headache, history of autoimmune disease, smoking, Tumarkin
crisis and the functional scale of the AAO-HNS. Hearing staging
was calculated by the audiogram obtained the day of inclusion for
each patient with definite MD and was defined as the mean of
four-tone average of 0.5, 1, 2 and 3 kHz according to the AAO-
HNS criteria: stage 1, #25 dB; stage 2, 26–40 dB; stage 3, 41–
70 dB; stage 4, .70 dB.
DNA extraction and genotyping
Blood samples from each subject were collected and genomic
DNA was isolated from peripheral blood leukocytes using the
QIAamp DNA Mini Kit (Quiagen), according to the manufac-
turer’s instructions. All genomic DNA was re-suspended in
nuclease free water for the following study.
The concentration of genomic DNA was measured using the
Qubit dsDNA BR Assay Kit (Invitrogen) and concentrations were
standardized to 50 ng/mL for genotyping. All samples were
genotyped using the ImmunoChip, a custom Illumina Infinium
high density genotyping array containing 196524 markers across
186 known autoimmunity risk loci [14],in the iScan genotyping
platform (Illumina Inc., San Diego, CA).
Quality controls
Samples were clustered together by using the Illumina Genome
Studio algorithm. Clusters were manually inspected and verified,
removal of single nucleotide polymorphisms (SNPs) with poor
clustering quality metrics (call frequency ,0.98, cluster separation
,0.4) was performed, and all SNPs with GenCall scores less than
NFKB1 Gene and Hearing in Meniere’s Disease
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0.15 were excluded. Quality controls (QC) were applied for all
individuals and genotyped SNPs by using PLINK software
(version 1.07) [16].
Samples with a genotype success rate of ,90% were excluded
from the analysis. The remaining samples were then evaluated for
duplicates or related individuals and one individual from each pair
was removed if the proportion of alleles share identical by descent
(IBD) .0.5. Samples with increased heterozygosity rate (,0.18
and . 0.45) and missing data between cases and controls P value
,1025, were then removed from the analysis. Finally, genetic
outliers determined by principal component analysis (PCA) were
removed from the analysis (. 3 standard deviation around the
mean). All familial cases were also excluded.
All the SNPs that did not meet the following criteria were
excluded from further analysis: genotype success rate ,90%,
minor allele frequency (MAF) ,5%, Hardy-Weinberg equilibrium
,1024 in controls and missing-genotype rate ,0.5%. All markers
Table 1. Single nucleotide polymorphisms in the NF-kB pathway with reported associations.
Chr Positiona rsID GENE (variant type) Phenotype Association P-Value Reference
6 138199417 rs610604 TNFAIP3 (intron) Psoriasis 5.5361025 [39]
5 150440097 rs2233287 TNIP1(intron) Asthma, systemic sclerosis 0.039, 6.1761024 [40,41]
5 150438988 rs1422673 TNIP1(intron) Asthma 0.011 [40]
2 61136129 rs13031237 REL (intron) Rheumatoid Arthritis 7.2961023 [42]
22 21939675 rs5754217 UBE2L3 (intron) SLE 0.012 [43]
22 21917190 rs131654 UBE2L3 (intron) SLE 1.1261027 [44]
22 21932068 rs181362 UBE2L3 (intron) HDL cholesterol 3.7261024 [45]
4 103434253 rs3774937 NFkB1 (intron) Primary biliary cirrhosis, Body Weight 1.5610210 0.041 [46, dbGaPb]
4 103475444 rs4648011 NFkB1 (intron) Body Weight 0.040 [dbGaPb]
aNCBI human genome build 37 coordinates.
bhttp://www.ncbi.nlm.nih.gov/gap [38].
doi:10.1371/journal.pone.0112171.t001
Table 2. Clinical features of patients with Meniere’s disease and uni or bilateral sensorineural hearing loss.
VARIABLES BILATERAL (n = 168) UNILATERAL (n = 548) P-value
Age of onset, mean ± SD 46.6612.5 46.9612.1 0.743
Gender (% women) 60.4 56.6 0.404
Time course (years), mean ± SD 11.268.7 7.966.7 1.561025
Affected ear (%) Left (50.6) Right (49.4)
Hearing loss at diagnosis, mean ± SD 53.9616.6 48.9617.3 0.003
Migraine, n (%) 25 (14.8) 56 (10.2) 0.719
History autoimmune disease, n (%) 36 (21.4) 62 (11.3) 0.003
Smoking, n (%) 40 (23.8) 134 (29.9) 0.882
Hearing stage, n (%)
1 7 (4.2) 58 (12.6) 8.061026
2 28 (16.6) 116 (21.2)
3 78 (46.4) 260 (47.4)
4 48 (28.5) 69 (12.5)
Hearing stage, mean ± SD 3.0160.8 2.6860.9 3.061026
Turmakin crisis, n (%) 44 (26.1) 77 (14.1) 0.001
Functional scale, n (%)
1 28 (16.6) 98 (17.9) 0.964
2 46 (27.3) 158 (28.8)
3 36 (21.4) 104 (18.9)
4 25 (14.8) 79 (14.4)
5 16 (9.5) 46 (8.3)
6 3 (1.7) 7 (1.2)
Age of onset, time course years and hearing loss at diagnosis were compared by unpaired Student’s t test. Qualitative variables were compared by
Chi-squared test.
doi:10.1371/journal.pone.0112171.t002
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in chromosome X were also excluded. After QC, 96899 SNPs
remained with a MAF.0.05 for statistical analysis.
Statistical analysis
After all QC, 689 cases (521 unilateral, 168 bilateral) and 1475
controls remained for further analyses. We have evaluated the
association between each SNPs and patients with uni or bilateral
MD. Allelic and genotype frequencies were compared between
patients and controls by using x2 test and calculating the odds
ratios (OR) and 95% confidence intervals (CIs) using PLINK
(version 1.07). P-values were adjusted by genomic control. The
power was computed as the probability of detecting an association
at the 0.05 significance level, assuming an OR = 1.5 (small effect
size). Power analysis was estimated using the Quanto v1.2.4
software (Department of Preventive Medicine University of
Southern California, CA, USA).
Moreover, among the SNPs compared above, we selected those
SNPs which have been previously associated with other immune-
mediated diseases, in the following genes: NFKB1 (rs3774937,
rs4648011), REL (rs13031237), UBE2L3 (rs5754217, rs131654,
rs181362), TNFAIP3 (rs610604) and TNIP1 (rs2233287,
rs1422673) (Table 1). To assess if any of these variants have any
effect on the clinical course of patients with MD. The median time
to reach hearing loss .40 dB (hearing stage 3 or 4) for each
genotype/allele was calculated according to the Kaplan–Meier
method and survival curves were compared using the log-rank test
(IBM SPSS Statistics 20.0). The p values were corrected, according
to the Bonferroni’s method, for the number of comparison made
for each gene. p,0.05 was considered statistically significant.
Validation of rs3774937 and rs4648011 genotyping
Case samples were also genotyped for two SNPs in the NFKB1
gene (rs3774937 and rs4648011) with a TaqMan 59 allelic
discrimination assay according to manufactures’ instructions (Life
Technologies). Amplifications were performed in an ABI 7500
Fast Real-Time PCR System (LT) for continuous fluorescence
monitoring. The alleles were determined using the SDS 2.2.1
software (LT). Functional evaluation of these regulatory variants
was performed in silico by using the bioinformatics tools
HaploReg (http://www.broadinstitute.org/mammals/haploreg/
haploreg.php), seeQTL (http://www.bios.unc.edu/research/
genomic_software/seeQTL/) and RegulomeDB (http://
regulomedb.org/) to explore annotations of the noncoding
genome such as candidate regulatory SNPs, conservation across
mammals and its potential effects on regulatory motifs [17–19].
Results
Table 2 compares the basic clinical features of 716 patients with
uni and bilateral MD in our series. As we expected, patients with
bilateral SNHL had a longer duration of disease (p = 1.561025),
worse hearing loss at diagnosis (p = 0.003) and worse hearing stage
(p = 361026), a higher frequency of Tumarkin crises (p = 0.001)
and autoimmune disease comorbidities (p = 0.003). However, no
differences were observed in the age of onset or frequency of
migraine between patients with uni or bilateral SNHL.
Principal-component analysis (PCA) showed that cases and
controls had similar distributions of the top two eigenvectors in
both sets, suggesting a common genetic background for these study
subjects (Figure S1 in File S1). We found no evidence of
population stratification in the PCA.
Table 3. Effect of allelic variants in the NF-kB pathway on hearing loss progression in patients with Meniere’s disease.
Long-rank test (p-value)
GENE SNV UNILATERAL BILATERAL
TNFAIP3 (intron) rs610604 genotype 0.469 0.431
allele 0.045 0.385
TNIP1 (intron) rs2233287 genotype 0.806 0.505
allele 0.612 0.521
TNIP1 (intron) rs1422673 genotype 0.849 0.729
allele 0.303 0.365
REL (intron) rs13031237 genotype 0.276 0.053
allele 0.613 0.449
UBE2L3 (intron) rs5754217 genotype 0.779 0.276
allele 0.992 0.360
UBE2L3 (intron) rs131654 genotype 0.738 0.208
allele 0.606 0.196
UBE2L3 (intron) rs181362 genotype 0.779 0.276
allele 0.992 0.360
NFKB1 (intron) rs3774937 genotype (CC) 0.018* 0.160
allele (C) 0.009* 0.995
NFKB1 (intron) rs4648011 genotype (GG) 0.018* 0.420
allele (G) 0.003* 0.956
Mean time to reach stage 3 (.40 dB) was compared by Kaplan –Meier survival curves and long-rank test.
*corrected p values after Bonferroni’s method.
doi:10.1371/journal.pone.0112171.t003
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No single marker reached a genome-wide significant (p,1028)
when all cases and controls were compared. The top ten signals
found in patients with MD are shown in Table S1 in File S1. The
allelic frequencies of the selected variants in genes NFKB1, REL,
UBE2L3, TNFAIP3 and TNIP1 in patients and controls are
shown in Tables S2, S3, S4, S5, and S6 in File S1. There was no
significant difference among patients with uni or bilateral SNHL
for any of the SNPs studied (p.0.05). We also stratified patients in
two groups according to the presence of uni or bilateral SNHL
and compared each group with controls, but none of the allelic
variants reached a genome-wide significance. Moreover, none of
the selected variants were associated with comorbidities such as
autoimmune disorder or migraine.
We also analyzed the time course of hearing loss in patients with
uni or bilateral SNHL for all the functional allelic variants
previously selected in the NF-kB pathway. Kaplan-Meier analysis
showed that functional allelic variants on REL, TNFAIP3, REL
and TNIP1 genes did not influence the auditory prognosis in MD
(Table 3). However, two SNP in the NFKB1 gene (rs3774937 and
rs4648011) were associated with a faster hearing loss progression
in patients with unilateral SNHL (n = 490). So, patients carrying C
allele in rs3774937 and G allele in rs4648011, respectively,
reduced in 2 years the mean time to reach hearing stage 3 (.
40 dB HL) (log-rank test, corrected p values were p = 0.009 for
rs3774937 and p = 0.003 for rs4648011, respectively; Figure 1).
So, the median of years to reach hearing stage 3 was 8, 8 or 11
years since the onset of disease for carriers of the genotype CC,
CT or TT in rs3774937, respectively (log-rank test, corrected p
value was p = 0.018). For rs4648011, we also found that the
median time to reach stage 3 was 7, 8 or 11 year since the onset of
disease for carriers of the genotype GG, GT or TT, respectively
(log-rank test, corrected p value p = 0.018). Remarkably, these
variants in the NFKB1 gene did not influence hearing in patients
with bilateral SNHL (p.0.05, 2N = 290). The allelic frequencies
of rs3774937-C and rs4648011-G were 0.31 and 0.37, respective-
ly. Both SNPs were validated in all cases by Taqman assays and
the correlation coefficient between both methods was 98%. These
variants showed high linkage disequilibrium (r2 = 0.67, D’ = 0.95;
Figure 2). The haplotype CG has a frequency of 32% and carriers
of this haplotype reached 40 dB 30 months earlier than the rest of
the haplotypes carriers (p = 0.002, Table 4). We also compared if
carriers of the CG haplotype had a faster hearing loss progression
than patients with either rs3774937-C or rs4648011-G alleles, but
no additive effect was found.
Finally, in silico analysis of these variants predicted changes in
the interaction with the following transcription factors: DMRT1,
LUN-1, YY1 for rs3774937 and Foxc1, Zfx for rs4648011.
Discussion
MD is probably a syndrome including a heterogeneous group of
patients with an immune-mediated disease and non-immune
mediated mechanisms. The 1995 clinical definition of the AAO-
HNS does not discriminate these clinical variants [15].
Our results show that allelic variants in the NFKB1 gene
influence the hearing outcome in patients with unilateral MD.
Although these markers are not associated with an increased
susceptibility to develop MD, they probably modify the interaction
of NFKB1 with other transcription factors conditioning the
inflammatory response in the inner ear. Our study has enough
power to detect an association between rs3774937 and rs4648011
and unilateral SNHL patients (.98% for both SNPs). However,
the lack of association found in bilateral SNHL patients can be due
to the smaller sample size in this cohort, resulting in a lack of
power to detect a susceptibility association (power 70% and 66%,
respectively). These intronic markers in the NFKB1 gene are
located in chromosome 4q24 and they have been strongly
associated with primary biliary cirrhosis [45].
Genetic association studies in MD have been limited to case-
control studies based on candidate-gene approaches in small series
Figure 1. Variants in NFKB1 gene and hearing outcome in patients with MD were compared by Kaplan-Meier survival curves and the
log-rank test. A. Carriers of the C allele in rs3774937 showed a shorter time to reach hearing stage 3 (.40 dB). B. Carriers of the G allele in rs4648011
also reduced in 2 years the mean time to reach hearing stage 3 (log-rank test, p = 0.009 for rs3774937 and p = 0.003 for rs4648011).
doi:10.1371/journal.pone.0112171.g001
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with low power and replication studies have failed to confirm
previous associations [20–22]. The introduction of technology of
genotyping-based arrays after finishing the Human Genome
Project [23] and the International HapMap Project [24] have
changed the approach for gene discovery in complex diseases to
large-scale testing where every gene in the human genome is tested
for association with a disease of interest.
The Immunochip project was a collaborative Consortium
among 12 immune-mediated disease groups (autoimmune thyroid
disease, ankylosing spondylitis, celiac disease, Crohn’s disease, IgA
deficiency, multiple sclerosis, primary biliary cirrhosis, psoriasis,
rheumatoid arthritis, SLE, type 1 diabetes and ulcerative colitis)
and the Welcome Trust Case Control Consortium (WTCCC).
The result was a high-density array containing 186 distinct
susceptibility loci associated with one or more immune-mediated
diseases [14]. The ImmunoChip has revealed mainly common
variants of modest effect size with odds ratios between 1.04 and
3.99 (mean = 1.29), when excluding the MHC region on most of
the immune-mediated diseases listed above [25–28] and other
diseases such as atopic dermatitis [29] or Behcet’s disease [30].
We have performed an exploratory genotyping study by using
the ImmunoChip including 716 patients and 1628 controls (689
and 1475, respectively after QC), but the clinical heterogeneity of
MD anticipates that this sample size is not enough to define the
susceptibility loci associated with MD. Previous findings and these
results suggest that patients with MD and uni and bilateral SNHL
have different genomic background since patients with bilateral
SNHL and MD have more frequent comorbid autoimmune
diseases [9], [10].
Autoimmunity has been proposed as a mechanism in patients
with bilateral SNHL and MD [2] and although preliminary
candidate gene studies found that bilateral MD was associated
with allelic variants of genes HLA-DRB1 [31], PTPN22 [32],
these findings have not been formally replicated in the current
study including 168 patients with bilateral MD, the largest
collection so far.
There are several reasons to explain our findings. The great
clinical heterogeneity of MD advances that several thousands of
patients will be required to perform a genome-wide association
study with enough power to find susceptibility loci with p values ,
1028. Although those numbers are possible by an international
multicenter study for unilateral MD, it is a real challenge to recruit
those numbers for bilateral MD.
Different studies suggest the role of innate immune response in
the hearing outcome of autoimmune inner ear disease [4], [6] and
MD [8]. So, in the present study we have found that two
regulatory variants of NFKB1 gene also influence long-term
progression of hearing loss in unilateral MD. Bioinformatics tools
predicted that these variants changed the interaction with the
following transcription factors: DMRT1, LUN-1, YY1 for
rs3774937 and Foxc1, Zfx for rs4648011. Since the NF-kB
pathway regulates proinflammatory cytokine production and cell
Figure 2. Linkage disequilibrium plot showing the haploblocks with the rs3774937 and rs4648011 (r2 = 0.67, D’ = 0.95).
doi:10.1371/journal.pone.0112171.g002
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survival and it mediates the duration of the inflammatory
response, these variants probably influence gene expression and
inflammation in MD. However, further studies with conditioned
cells (i.e., lymphoblasts with the homozygous variants) will be
necessary to define the effect of these variants in the gene
expression profile, since multiple interactions are possible in the
NF-kB network and the molecular mechanism remains unknown.
We have recently found that rs11096955 in TLR10 gene may
confer susceptibility to bilateral SNHL in patients with MD [8].
TLRs constitute one of primary defense mechanisms in infections
and some noninfectious diseases [33] and inadequate activation of
TLRs pathway has been reported in several autoimmune diseases
[34]. Since TLRs activates an intracellular signal via MyD88,
triggering a complex cascade (IRAK1-IRAK4-TRAF6, TAK1-
TAB1-TRAF6-UBC13, IKK complex) that leads to the induction
of a large range of proinflammatory genes via the transcription
factors NF-kB [35], we have selected functional variants in the
genes NFKB1, REL, UBE2L3, TNFAIP3 and TNIP1 to
evaluate their potential role in the outcome of MD. Overall, we
suggest that allelic variants in some genes of the innate immune
response such as TLR10 and NFKB1 may act as regulatory genes
able to modify the clinical progression of hearing in MD. By using
an NF-kB reporter mouse, it was demonstrated that the protective
action of NF-kB was exerted in connective tissue cells within the
spiral ligament. So, in the spiral ligament, type II fibrocytes are
activated following systemic inflammatory stress and immune-
mediated SNHL in humans may result in part from susceptibility
of type II fibrocytes [36]. An abnormal function of type II
fibrocytes would likely have a significant impact upon hearing
thresholds, since these cells have a critical role in K+ ion uptake
from perilymph. Moreover, the fact that steroids are potent
blockers of NF-kB pathway may explain the observed response to
systemic steroids in patients with sudden SNHL or MD.
Our study design has some limitations: the sample size is not
enough to detect differences for SNPs with MAF,0.05; however is
has been recently demonstrated that the effect of rare variants in
autoimmune loci is negligible [37]. We have only compared SNPs
included in the ImmunoChip and it is necessary to scan the entire
genome in complex diseases. Moreover, the great heterogeneity of
the disorder may raise concerns about the cost-effectiveness of this
approach. An alternative approach is to select multicase families
with MD and combine whole-exome sequencing with segregation
analysis to define novel or rare variants in candidate genes.
Genomic data fusion including phenotype-and pathway-based
analyses may help to decipher the complex genomic architecture
of MD.
Conclusions
Allelic variants rs3774937 and rs4648011 can modify hearing
outcome in patients with MD and unilateral SNHL. A patent
application number P201430716 has been submitted to the
Spanish Patent and Trademark Office.
Supporting Information
File S1 Figure S1, Scatter plot showing the principal
component analysis (PCA) in our Spanish samples compared with
different populations in HapMap. The eigenvalues for the first
three principal components accounted for most of the population
substructure in this analysis (77.5%). All individuals who were not
clustering with the main cluster (. 3 Standard deviation from
cluster center) were excluded from subsequent analysis. Using this
method we identified a total of 48 outliers individuals in our case-
control cohort. X-axis represents Principal Component 1 (PC1)
and Y-axis represents Principal Component 3 (PC3) in our
Spanish samples (diamonds), and the main populations in
HapMap: CEU, Northern European from Utah (squares),
CHB+JPB, Chinese in Beijing+ Japanese in Tokyo (triangles),
MEX (crosses), TSI, Tuscans from Italy (asterisks) and YRI,
Yoruba in Ibadan, Nigeria (circles). Table S1, Minor allelic
frequencies of the top 10 ranked signals obtained with the
Immunochip in patients with Meniere’s diasease. Table S2,
Minor allelic frequencies of 15 single nucleotide variants in the
TNFAIP3 gene in controls and patients with uni and bilateral
sensorineural hearing loss. Table S3, Minor allelic frequencies of
87 single nucleotide variants in the TNIP1 gene in controls and
patients with uni and bilateral sensorineural hearing loss. Table
S4, Minor allelic frequencies of 16 single nucleotide variants in the
REL gene in controls and patients with uni and bilateral
sensorineural hearing loss. Table S5, Minor allelic frequencies
of 34 single nucleotide variants in the UBE2L3 gene in controls
and patients with uni and bilateral sensorineural hearing loss.
Table S6, Minor allelic frequencies of 9 single nucleotide variants
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Table 4. Effect of rs3774937 (T.C) and rs4648011 (T.G) haplotypes on hearing loss in patients with Meniere’s disease.
Time to reach .40 dB (years, mean ± SD)
HAPLOTYPE (rs3774937, rs4648011) FREQUENCY (%) UNILATERAL BILATERAL
CG 33 860.48 1060.90
GT 5 861.12 1261.20
TT 62 1060.47 1260.67
Time to reach hearing .40 dB was compared by survival curves using the Kaplan-Meier method.
doi:10.1371/journal.pone.0112171.t004
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